KR20230048476A - 암 치료 시에 사용하기 위한 미르다메티닙과 리피라페닙의 공동 투여 - Google Patents

암 치료 시에 사용하기 위한 미르다메티닙과 리피라페닙의 공동 투여 Download PDF

Info

Publication number
KR20230048476A
KR20230048476A KR1020227038490A KR20227038490A KR20230048476A KR 20230048476 A KR20230048476 A KR 20230048476A KR 1020227038490 A KR1020227038490 A KR 1020227038490A KR 20227038490 A KR20227038490 A KR 20227038490A KR 20230048476 A KR20230048476 A KR 20230048476A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038490A
Other languages
English (en)
Korean (ko)
Inventor
루송 루오
지위 탕
바드레딘 에드리스
토드 웹스터 시어러
Original Assignee
베이진 리미티드
스프링웍스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이진 리미티드, 스프링웍스 테라퓨틱스, 인크. filed Critical 베이진 리미티드
Publication of KR20230048476A publication Critical patent/KR20230048476A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227038490A 2020-04-03 2021-04-02 암 치료 시에 사용하기 위한 미르다메티닙과 리피라페닙의 공동 투여 Pending KR20230048476A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005153P 2020-04-03 2020-04-03
US63/005,153 2020-04-03
PCT/US2021/025551 WO2021202981A1 (en) 2020-04-03 2021-04-02 Co-administration of mirdametinib and lifirafenib for use in treating cancers

Publications (1)

Publication Number Publication Date
KR20230048476A true KR20230048476A (ko) 2023-04-11

Family

ID=75674969

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038490A Pending KR20230048476A (ko) 2020-04-03 2021-04-02 암 치료 시에 사용하기 위한 미르다메티닙과 리피라페닙의 공동 투여

Country Status (21)

Country Link
US (1) US12667560B2 (enExample)
EP (1) EP4125842B1 (enExample)
JP (2) JP7748386B2 (enExample)
KR (1) KR20230048476A (enExample)
CN (1) CN116194095B (enExample)
AU (1) AU2021246141A1 (enExample)
BR (1) BR112022019914A2 (enExample)
CA (1) CA3174223A1 (enExample)
CL (1) CL2022002682A1 (enExample)
CO (1) CO2022015891A2 (enExample)
DK (1) DK4125842T3 (enExample)
ES (1) ES2985012T3 (enExample)
FI (1) FI4125842T3 (enExample)
HU (1) HUE067894T2 (enExample)
IL (1) IL296878A (enExample)
MX (1) MX2022012351A (enExample)
PE (1) PE20231211A1 (enExample)
PL (1) PL4125842T3 (enExample)
PT (1) PT4125842T (enExample)
TW (1) TWI893097B (enExample)
WO (1) WO2021202981A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US20230293464A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of pancreatic ductal adenocarcinoma with mirdametinib
MX2024011403A (es) * 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
WO2023209611A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib
EP4601631A4 (en) * 2022-10-14 2026-04-08 Springworks Therapeutics Inc COMBINATION INTENDED FOR USE IN CANCER TREATMENT

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1562601A1 (en) 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
WO2006134469A1 (en) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Methods of preparing mek inhibitor
WO2007042885A2 (en) 2005-10-07 2007-04-19 Pfizer Products Inc. Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2016248376B2 (en) 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
WO2019113345A1 (en) 2017-12-06 2019-06-13 Spyro Mousses Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
PL4125842T3 (pl) 2020-04-03 2024-10-14 Beigene, Ltd. Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
MX2024011403A (es) 2022-03-17 2024-09-23 Springworks Therapeutics Inc Tratamiento con mirdametinib.
PE20242177A1 (es) 2022-03-17 2024-11-07 St Jude Childrens Res Hospital Inc Tratamiento del glioma de bajo grado con mirdametinib

Also Published As

Publication number Publication date
US20230128315A1 (en) 2023-04-27
IL296878A (en) 2022-12-01
HUE067894T2 (hu) 2024-11-28
ES2985012T3 (es) 2024-11-04
CN116194095A (zh) 2023-05-30
PL4125842T3 (pl) 2024-10-14
EP4125842A1 (en) 2023-02-08
CO2022015891A2 (es) 2023-05-08
JP2023521036A (ja) 2023-05-23
EP4125842B1 (en) 2024-06-05
TWI893097B (zh) 2025-08-11
PT4125842T (pt) 2024-08-06
US12667560B2 (en) 2026-06-30
JP7748386B2 (ja) 2025-10-02
PE20231211A1 (es) 2023-08-17
MX2022012351A (es) 2023-03-13
DK4125842T3 (da) 2024-07-22
FI4125842T3 (fi) 2024-08-06
JP2025120501A (ja) 2025-08-15
CA3174223A1 (en) 2021-10-07
CL2022002682A1 (es) 2023-06-16
CN116194095B (zh) 2024-09-13
AU2021246141A1 (en) 2022-12-01
TW202207910A (zh) 2022-03-01
BR112022019914A2 (pt) 2022-12-13
WO2021202981A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7748386B2 (ja) がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与
Filos et al. Intrathecal clonidine as a sole analgesic for pain relief after cesarean section
MXPA04012070A (es) Agente terapeutico para vejiga hiperactiva.
JP2022519721A (ja) 睡眠時無呼吸を治療するための方法および組成物
Mantz Alpha2-adrenoceptor agonists: analgesia, sedation, anxiolysis, haemodynamics, respiratory function and weaning
Dahl et al. Immediate and prolonged effects of pre–versus postoperative epidural analgesia with bupivacaine and morphine on pain at rest and during mobilisation after total knee arthroplasty
Moyao-García et al. A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children
EP3982970A1 (en) New treatment of sma
CN101754760A (zh) 用以改善伴随着前列腺肥大的下尿路症状的药物组合物
RU2671575C2 (ru) Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
Arora Prophylactic tramadol versus dexmedetomidine for prevention of shivering during spinal anaesthesia
JP2022520276A (ja) ベンズイミダゾール誘導体化合物を含む医薬組成物
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
JP2005516977A (ja) 尿失禁の処置での４−（２−フルオロフェニル）−６−メチル−２−（１−ピペラジニル）チエノ（２，３−ｄ−ピリミジン）の使用
CN114466683A (zh) 治疗方法及其用途
US4687771A (en) Method for treatment of male impotence
AU716972B2 (en) Method for treating bipolar disorder
US12303503B1 (en) Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
WO1999007369A1 (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
RU2001107831A (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
Rauck et al. Conversion and titration from oxycodone to oxymorphone extended release in patients with chronic low back pain
HK40015061B (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
Podolsky et al. Randomized clinical trial of the safety and efficacy of oxymorphone extended release for degenerative disc disease in opioid-naive patients
CA2586231A1 (en) Method for treating hiv infection through co-administration of tipranavir and uk-427, 857

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000